AbbVie Inc. is 91.9x more valuable than Travere Therapeutics, Inc. by market capitalization ($399.47 B vs $4.35 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | TVTX | ABBV |
|---|---|---|
| Market cap | $4.35 B | $399.47 B |
| US-listed rank | #1502 | #28 |
| Revenue (latest FY) | $490.73M | $61.16B |
| Net income (latest FY) | -$25.55M | $4.23B |
| Net margin | -5.2% | 6.9% |
| P/E (trailing FY) | - | 94.5 |
| SEC filings | 1,240 | 1,008 |
AbbVie Inc. is 91.9x more valuable than Travere Therapeutics, Inc. by market capitalization ($399.47 B vs $4.35 B).
In their latest fiscal years, Travere Therapeutics, Inc. reported $490.73M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Travere Therapeutics, Inc. and AbbVie Inc., or browse the full rankings.